About
CatalYm

Pioneers in neutralizing GDF-15
to overcome cancer therapy resistance

CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors. GDF-15, an immunosuppressant important for feto-maternal tolerance, is hijacked by cancer cells to evade immune system attacks. Visugromab, CatalYm’s lead antibody, has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1. CatalYm is now advancing into Phase 2b studies to confirm visugromab as a new class of cancer immunotherapy in a broad range of anti-cancer regimens.

Our Science

Our Pipeline

Latest News

Leadership Team

+
Managing Director and
Chief Executive Officer (CEO)
+
Chief Scientific Officer (CSO)
+
Chief Medical Officer (CMO)
+
Chief Financial Officer (CFO)

Board of Directors

John Haurum serves as the Chairman of the Board of Directors at CatalYm. In addition, John is a non-executive director of Adcendo, Agomab, Neophore, Solid Therapeutics, Storm and SynKlino. Previously, (...)

Read more
Board member

Andreas Wallnöfer has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team. Andreas (...)

Read more
Independent board member

Roy Baynes received his MB, BCh (Bachelor of Medicine and Surgery) from the University of Witwatersrand, where he also received an MMed (specialist registration) and completed a PhD exploring mechanisms (...)

Read more
Independent board member

Hans van Eenennaam is CEO and founder of IMMIOS and Chief Scientific Officer at Sairopa. Previously, he served as Chief Scientific Officer of AIMM Therapeutics and as Executive Vice President of Antibody (...)

Read more
Board member

Jonathan is a Partner at Brandon Capital where he heads European operations and serves on the boards of Pheon Therapeutics, Myricx Bio, Astronautx and NRG Therapeutics. Previously, he was Managing Director (...)

Read more
Board member

Marc Lohrmann is Managing Partner at Vesalius Biocapital III and has over 20 years of industry experience. He joined Vesalius Biocapital in 2012 as a venture partner and became a Managing Partner in (...)

Read more
Board observer

Marianne Uteng PhD is a Managing Director at NVF in Basel, Switzerland. Prior to that, she worked in Novartis Global Drug Development, and in the Pre-Clinical Safety Department where she led teams delivering (...)

Read more
Board observer

Nathalie Weitemeyer is a Senior Investment Manager at Bayern Kapital, the venture capital organisation of the Free State of Bavaria. She has been responsible for life science and medical technology (...)

Read more
Board member

Oskar Slotboom is a managing partner at BioGeneration Ventures (BGV). He joined BGV in 2016, strengthening the team with his commercial, business development and consulting experience. Oskar started (...)

Read more
Board member

Rogier Rooswinkel is General Partner at Forbion where he is responsible for evaluation and structuring of new investment opportunities across all disease areas with an emphasis on oncology. Prior to (...)

Read more

Our Investors

Our mission is supported by a syndicate
of renowned life science investors

WordPress Cookie Notice by Real Cookie Banner